Imaging of cerebral α 4 β 2 nicotinic acetylcholine receptors with (−)-[ 18 F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain

• Published in: NeuroImage (Orlando, Fla.) Vol. 141; pp. 71 - 80
• Main Authors: Hillmer, A T, Esterlis, I, Gallezot, J D, Bois, F, Zheng, M Q, Nabulsi, N, Lin, S F, Papke, R L, Huang, Y, Sabri, O, Carson, R E, Cosgrove, K P
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Limited 01.11.2016
• Subjects: Acetylcholine receptors (nicotinic); Alzheimer's disease; Binding sites; Cerebellum; Cortex; Data processing; Equilibrium; Experiments; Human subjects; Injection; Mental disorders; Neurodegenerative diseases; Neuroimaging; Physostigmine; Positron emission tomography; Schizophrenia; Studies; Substantia grisea; Thalamus
• ISSN: 1053-8119; 1095-9572
• DOI: 10.1016/j.neuroimage.2016.07.026

The positron emission tomography (PET) radioligand (−)-[18F]flubatine is specific to α4β2⁎ nicotinic acetylcholine receptors (nAChRs) and has promise for future investigation of the acetylcholine system in neuropathologies such as Alzheimer's disease, schizophrenia, and substance use disorders. The two goals of this work were to develop a simplified method for α4β2⁎ nAChR quantification with bolus plus constant infusion (B/I) (−)-[18F]flubatine administration, and to assess the radioligand's sensitivity to acetylcholine fluctuations in humans. Healthy human subjects were imaged following either bolus injection (n=8) or B/I (n=4) administration of (−)-[18F]flubatine. The metabolite-corrected input function in arterial blood was measured. Free-fraction corrected distribution volumes (VT/fP) were estimated with modeling and graphical analysis techniques. Next, sensitivity to acetylcholine was assessed in two ways: 1. A bolus injection paradigm with two scans (n=6), baseline (scan 1) and physostigmine challenge (scan 2; 1.5mg over 60min beginning 5min prior to radiotracer injection); 2. A single scan B/I paradigm (n=7) lasting up to 240min with 1.5mg physostigmine administered over 60min beginning at 125min of radiotracer infusion. Changes in VT/fP were measured. Baseline VT/fP values were 33.8±3.3mL/cm3 in thalamus, 12.9±1.6mL/cm3 in cerebellum, and ranged from 9.8 to 12.5mL/cm3 in other gray matter regions. The B/I paradigm with equilibrium analysis at 120min yielded comparable VT/fP values with compartment modeling analysis of bolus data in extrathalamic gray matter regions (regional means <4% different). Changes in VT/fP following physostigmine administration were small and most pronounced in cortical regions, ranging from 0.8 to 4.6% in the two-scan paradigm and 2.8 to 6.5% with the B/I paradigm. These results demonstrate the use of B/I administration for accurate quantification of (−)-[18F]flubatine VT/fP in 120min, and suggest possible sensitivity of (−)-[18F]flubatine binding to physostigmine-induced changes in acetylcholine levels.